Our results show that (1) pCR/0 is obtained in 24.8 % and pCR/is in 46.8 % of the patients; (2) nonluminal/HER2+ subclass and neoadjuvant trastuzumab treatment for more than 12 weeks are predictive factors of pCR/0; (3) pCR (calculated either including or not residual noninvasive cancer cells) is predictive of DFS and CSS only in the nonluminal/HER2+ subclass; and (4) luminal B/HER2+ tumors and pathological stage 0–I disease at surgery are associated with a better DFS and CSS. This evidence concerns the gene ERBB2 and cancer.